The  ||| S:0 E:4 ||| DT
interaction  ||| S:4 E:16 ||| NN
between  ||| S:16 E:24 ||| IN
medical  ||| S:24 E:32 ||| JJ
burden  ||| S:32 E:39 ||| NN
and  ||| S:39 E:43 ||| CC
anticholinergic  ||| S:43 E:59 ||| JJ
cognitive  ||| S:59 E:69 ||| JJ
burden  ||| S:69 E:76 ||| NN
on  ||| S:76 E:79 ||| IN
neuropsychological  ||| S:79 E:98 ||| JJ
function  ||| S:98 E:107 ||| NN
in  ||| S:107 E:110 ||| IN
a  ||| S:110 E:112 ||| DT
geriatric  ||| S:112 E:122 ||| JJ
primary  ||| S:122 E:130 ||| JJ
care  ||| S:130 E:135 ||| NN
sample  ||| S:135 E:142 ||| NN
Poorer  ||| S:142 E:149 ||| NNP
neuropsychological  ||| S:149 E:168 ||| JJ
function  ||| S:168 E:177 ||| NN
is  ||| S:177 E:180 ||| VBZ
associated  ||| S:180 E:191 ||| VBN
with  ||| S:191 E:196 ||| IN
increased  ||| S:196 E:206 ||| JJ
medical  ||| S:206 E:214 ||| JJ
burden  ||| S:214 E:221 ||| NN
( ||| S:221 E:222 ||| -LRB-
MB ||| S:222 E:224 ||| NNP
)  ||| S:224 E:226 ||| -RRB-
and  ||| S:226 E:230 ||| CC
the  ||| S:230 E:234 ||| DT
use  ||| S:234 E:238 ||| NN
of  ||| S:238 E:241 ||| IN
more  ||| S:241 E:246 ||| RBR
anticholinergic  ||| S:246 E:262 ||| JJ
medications ||| S:262 E:273 ||| NN
.  ||| S:273 E:275 ||| .
However ||| S:275 E:282 ||| RB
,  ||| S:282 E:284 ||| ,
the  ||| S:284 E:288 ||| DT
interaction  ||| S:288 E:300 ||| NN
between  ||| S:300 E:308 ||| IN
MB  ||| S:308 E:311 ||| NNP
and  ||| S:311 E:315 ||| CC
anticholinergic  ||| S:315 E:331 ||| JJ
cognitive  ||| S:331 E:341 ||| JJ
burden  ||| S:341 E:348 ||| NN
( ||| S:348 E:349 ||| -LRB-
AB ||| S:349 E:351 ||| NNP
)  ||| S:351 E:353 ||| -RRB-
on  ||| S:353 E:356 ||| IN
neuropsychological  ||| S:356 E:375 ||| JJ
performance  ||| S:375 E:387 ||| NN
is  ||| S:387 E:390 ||| VBZ
unknown ||| S:390 E:397 ||| JJ
.  ||| S:397 E:399 ||| .
In  ||| S:399 E:402 ||| IN
a  ||| S:402 E:404 ||| DT
sample  ||| S:404 E:411 ||| NN
of  ||| S:411 E:414 ||| IN
290  ||| S:414 E:418 ||| CD
elderly  ||| S:418 E:426 ||| JJ
primary  ||| S:426 E:434 ||| JJ
care  ||| S:434 E:439 ||| NN
patients ||| S:439 E:447 ||| NNS
,  ||| S:447 E:449 ||| ,
those  ||| S:449 E:455 ||| DT
with  ||| S:455 E:460 ||| IN
a  ||| S:460 E:462 ||| DT
greater  ||| S:462 E:470 ||| JJR
level  ||| S:470 E:476 ||| NN
of  ||| S:476 E:479 ||| IN
AB  ||| S:479 E:482 ||| NNP
demonstrated  ||| S:482 E:495 ||| VBD
poorer  ||| S:495 E:502 ||| JJR
Total  ||| S:502 E:508 ||| JJ
Index  ||| S:508 E:514 ||| NN
performance  ||| S:514 E:526 ||| NN
on  ||| S:526 E:529 ||| IN
the  ||| S:529 E:533 ||| DT
Repeatable  ||| S:533 E:544 ||| NNP
Battery  ||| S:544 E:552 ||| NNP
for  ||| S:552 E:556 ||| IN
the  ||| S:556 E:560 ||| DT
Assessment  ||| S:560 E:571 ||| NNP
of  ||| S:571 E:574 ||| IN
Neuropsychological  ||| S:574 E:593 ||| NNP
Status  ||| S:593 E:600 ||| NNP
( ||| S:600 E:601 ||| -LRB-
RBANS ||| S:601 E:606 ||| NNP
) ||| S:606 E:607 ||| -RRB-
.  ||| S:607 E:609 ||| .
Further ||| S:609 E:616 ||| RB
,  ||| S:616 E:618 ||| ,
an  ||| S:618 E:621 ||| DT
interaction  ||| S:621 E:633 ||| JJ
effect  ||| S:633 E:640 ||| NN
was  ||| S:640 E:644 ||| VBD
noted  ||| S:644 E:650 ||| VBN
such  ||| S:650 E:655 ||| JJ
that  ||| S:655 E:660 ||| IN
there  ||| S:660 E:666 ||| EX
was  ||| S:666 E:670 ||| VBD
a  ||| S:670 E:672 ||| DT
greater  ||| S:672 E:680 ||| JJR
anticholinergic  ||| S:680 E:696 ||| JJ
effect  ||| S:696 E:703 ||| NN
on  ||| S:703 E:706 ||| IN
RBANS  ||| S:706 E:712 ||| NNP
Total ||| S:712 E:717 ||| NNP
,  ||| S:717 E:719 ||| ,
Attention ||| S:719 E:728 ||| NNP
,  ||| S:728 E:730 ||| ,
and  ||| S:730 E:734 ||| CC
Delayed  ||| S:734 E:742 ||| NNP
Memory  ||| S:742 E:749 ||| NNP
Index  ||| S:749 E:755 ||| NNP
scores  ||| S:755 E:762 ||| NNS
for  ||| S:762 E:766 ||| IN
participants  ||| S:766 E:779 ||| NNS
with  ||| S:779 E:784 ||| IN
fewer  ||| S:784 E:790 ||| JJR
MB ||| S:790 E:792 ||| NNP
.  ||| S:792 E:794 ||| .
Participants  ||| S:794 E:807 ||| NNS
with  ||| S:807 E:812 ||| IN
more  ||| S:812 E:817 ||| JJR
MB  ||| S:817 E:820 ||| NNP
demonstrated  ||| S:820 E:833 ||| VBD
poorer  ||| S:833 E:840 ||| JJR
performance  ||| S:840 E:852 ||| NN
irrespective  ||| S:852 E:865 ||| NN
of  ||| S:865 E:868 ||| IN
their  ||| S:868 E:874 ||| PRP$
level  ||| S:874 E:880 ||| NN
of  ||| S:880 E:883 ||| IN
AB ||| S:883 E:885 ||| NNP
.  ||| S:885 E:887 ||| .
These  ||| S:887 E:893 ||| DT
results  ||| S:893 E:901 ||| NNS
indicate  ||| S:901 E:910 ||| VBP
that  ||| S:910 E:915 ||| IN
MB  ||| S:915 E:918 ||| NNP
effects  ||| S:918 E:926 ||| NNS
may  ||| S:926 E:930 ||| MD
be  ||| S:930 E:933 ||| VB
overshadowed  ||| S:933 E:946 ||| VBN
by  ||| S:946 E:949 ||| IN
anticholinergic  ||| S:949 E:965 ||| JJ
effects  ||| S:965 E:973 ||| NNS
in  ||| S:973 E:976 ||| IN
older  ||| S:976 E:982 ||| JJR
patients ||| S:982 E:990 ||| NNS
.  ||| S:990 E:992 ||| .
